Ignite Creation Date:
2024-05-06 @ 7:24 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT06001385
Status:
RECRUITING
Last Update Posted:
2024-06-11
First Post:
2023-08-14
Brief Title:
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Sponsor:
Center for International Blood and Marrow Transplant Research
Organization:
Center for International Blood and Marrow Transplant Research
Study Overview
Official Title:
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPTIMIZE
Brief Summary:
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide PTCy in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor MMUD The main questions it aims to answer are
Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant
Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease GvHD as the standard dose of PTCy
Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant
Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease GvHD as the standard dose of PTCy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None